Racine Eric, Aspler John, Forlini Cynthia, Chandler Jennifer A
Kennedy Inst Ethics J. 2017;27(1):1-41. doi: 10.1353/ken.2017.0002.
Given advances in Alzheimer's disease (AD) research, some experts have proposed a state of "preclinical" AD to describe asymptomatic individuals displaying certain biomarkers. The diagnostic accuracy of these biomarkers remains debated; however, given economic pressures, this "diagnosis" may eventually reach consumers. Since evidence-based prevention and treatment options remain only modestly effective, patients may turn to complementary and alternative medicine (CAM). We explore ethical challenges associated with CAM use in preclinical AD. We first consider these issues through the liberal lens, which emphasizes informed choice while occasionally disregarding the complexity of decision making, at least as currently applied to CAM policies. We then broaden the liberal lens with a socio-contextual lens, which describes the impact of social context on choice. Finally, we describe an alternate lens (contextualized liberalism) and its practical health and policy implications while 1) building on the liberal commitment to autonomy and 2) recognizing contextual determinants of choice.
鉴于阿尔茨海默病(AD)研究的进展,一些专家提出了“临床前”AD的状态,以描述表现出某些生物标志物的无症状个体。这些生物标志物的诊断准确性仍存在争议;然而,鉴于经济压力,这种“诊断”最终可能会面向消费者。由于基于证据的预防和治疗选择效果仍较为有限,患者可能会转向补充和替代医学(CAM)。我们探讨了临床前AD中使用CAM相关的伦理挑战。我们首先通过自由主义视角来考虑这些问题,该视角强调知情选择,同时偶尔会忽视决策的复杂性,至少目前应用于CAM政策时是这样。然后我们用社会情境视角拓宽自由主义视角,该视角描述了社会情境对选择的影响。最后,我们描述了另一种视角(情境化自由主义)及其实际的健康和政策意义,同时1)基于对自主性的自由主义承诺,2)认识到选择的情境决定因素。